analysis by هم افزایان بورس تهران about Stock دابور on 8/7/2025

#Medication 📌 In equity shares that have an analytical P/E 4 or even less than 4 units have increased over the past month, and as it was previously mentioned, the low analytical P/E is not the reason for buying or growing in the short term. 📌 Summary ##Deyina with 4 pure profit sales equivalent to 1.6 efforts and 4 units in analytical p/e and 60 % profit division. ##Caspian with 4.6 sales and pure profit equivalent to 1.6 and 3.9 -unit analytical P/E and 80 % division ##Dafara with 4 sales and 660 billion profits received from datables and migrations and ultimately 1.2 net profit and 4 analytical P/E and 90 % division ##Dezagres with 4.1 sales and pure profit equivalent to 1.5 integrity and 3.7 -unit analytical P/E and 40 % division ##Dabor with 2.7 sales and pure profit equivalent to 700 billion and 4.5 units analytical p/e 📌 Group of medicine Because of the nature of the industry, it does not have a sharp decline in demand than most of the risk groups, and the most important risk is the issue of high demand collection! The quality control of the industry is such that they are extremely sensitive to the power outage and if they have a power outage during the production process, the whole material that was in the process must be destroyed. A number of companies like #Dabur and #Disagros have had the maximum profit in previous years, but this year it is right to divide 40 ~ 50 %. You see, the industry is facing the risk of high claims, and if the company wants to divide the entire profit, it has to finance at a rate of 40 % and eliminate the financial cost of the company. So by the way, companies that have average division have taken into account both the interests of the shareholder and the company's interests that are finally secured. August 16th